共 93 条
[1]
Grantham JJ(2006)Volume progression in polycystic kidney disease N Engl J Med 354 2122-2130
[2]
Torres VE(2016)Autosomal dominant polycystic kidney disease: core curriculum 2016 Am J Kidney Dis 67 792-810
[3]
Chapman AB(2006)Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes Clin J Am Soc Nephrol 1 148-157
[4]
Chebib FT(2012)Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 7 479-486
[5]
Torres VE(2003)Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist Nat Med 9 1323-1326
[6]
Grantham JJ(2004)Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease Nat Med 10 363-364
[7]
Chapman AB(2005)Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat J Am Soc Nephrol 16 846-851
[8]
Torres VE(2008)Vasopressin directly regulates cyst growth in polycystic kidney disease J Am Soc Nephrol 19 102-108
[9]
Chapman AB(2014)Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury J Pharmacol Exp Ther 349 258-267
[10]
Bost JE(2012)Tolvaptan in patients with autosomal dominant polycystic kidney disease N Engl J Med 367 2407-2418